Telithromycin blocks neuromuscular transmission and inhibits nAChR currents in vitro

Toxicology Letters

Volumn 194, Issue 3, 2010, Pages 66-69

  Liu, Chang Ning ^a   Somps, Chris J ^a  

^a PFIZER INC   (United States)

Author keywords

D Tubocurarine; Ketek; Muscle contraction; Neuromuscular junction; Patch clamp; TE671

Indexed keywords

CLARITHROMYCIN; NICOTINIC RECEPTOR; TELITHROMYCIN; TUBOCURARINE CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIAPHRAGM MUSCLE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; INTRACELLULAR RECORDING; MALE; MEDULLOBLASTOMA; MEMBRANE CURRENT; MUSCLE TWITCH; NERVE STIMULATION; NEUROMUSCULAR BLOCKING; NEUROMUSCULAR SYNAPSE; NONHUMAN; PATCH CLAMP; PHRENIC NERVE; POSTSYNAPTIC INHIBITION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TISSUE SECTION; WHOLE CELL;

ANIMALS; ANTI-BACTERIAL AGENTS; CELL LINE; CLARITHROMYCIN; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; KETOLIDES; MALE; MUSCLE CONTRACTION; MUSCLE, SKELETAL; NEUROMUSCULAR BLOCKING AGENTS; NICOTINIC ANTAGONISTS; PATCH-CLAMP TECHNIQUES; RATS; RATS, SPRAGUE-DAWLEY; SYNAPTIC POTENTIALS; TUBOCURARINE;

ANIMALIA; RATTUS;

EID: 77950860198     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxlet.2010.02.005     Document Type: Article

References (36)

1. Absher J.R., Bale J.F. Aggravation of myasthenia gravis by erythromycin. J. Pediatr. 1991, 119:155-156.
2. Almon R.R., Appel S.H. Interaction of myasthenic serum globulin with the acetylcholine receptor. Biochim. Biophys. Acta 1975, 393:66-77.
3. Argov Z., Mastaglia F.L. Drug therapy: disorders of neuromuscular transmission caused by drugs. N. Engl. J. Med. 1979, 301:409-413.
4. Bertino J.S. Severe hepatotoxicity of telithromycin. Ann. Intern. Med. 2006, 145:472. (author reply 472).
5. Bowman W.C. Neuromuscular block. Br. J. Pharmacol. 2006, 147(Suppl. 1):S277-S286.
6. Brown S.D. Benefit-risk assessment of telithromycin in the treatment of community-acquired pneumonia. Drug Saf. 2008, 31:561-575.
7. Demolis J.L., Vacheron F., Cardus S., Funck-Brentano C. Effect of single and repeated oral doses of telithromycin on cardiac QT interval in healthy subjects. Clin. Pharmacol. Ther. 2003, 73:242-252.
8. Drachman D.B., Angus C.W., Adams R.N., Michelson J.D., Hoffman G.J. Myasthenic antibodies cross-link acetylcholine receptors to accelerate degradation. N. Engl. J. Med. 1978, 298:1116-1122.
9. Engel A.G. Morphologic and immunopathologic findings in myasthenia gravis and in congenital myasthenic syndromes. J. Neurol. Neurosurg. Psychiatr. 1980, 43:577-589.
10. Ferry C.B., Kelly S.S. The nature of the presynaptic effects of (+)-tubocurarine at the mouse neuromuscular junction. J. Physiol. 1988, 403:425-437.
11. Grassi F., Giovannelli A., Fucile S., Mattei E., Eusebi F. Cholinergic responses in cloned human TE671/RD tumour cells. Pflug. Arch. 1993, 425:117-125.
12. Grob D., Brunner N., Namba T., Pagala M. Lifetime course of myasthenia gravis. Muscle Nerve 2008, 37:141-149.
13. Hatanaka Y., Zamami Y., Koyama T., Hobara N., Jin X., Kitamura Y., Kawasaki H. A ketolide antibiotic, telithromycin, inhibits vascular adrenergic neurotransmission in the rat mesenteric vascular bed. Br. J. Pharmacol. 2008, 155:826-836.
14. Howard F.M., Lennon V.A., Finley J., Matsumoto J., Elveback L.R. Clinical correlations of antibodies that bind, block, or modulate human acetylcholine receptors in myasthenia gravis. Ann. N. Y. Acad. Sci. 1987, 505:526-538.
15. Jennett A.M., Bali D., Jasti P., Shah B., Browning L.A. Telithromycin and myasthenic crisis. Clin. Infect. Dis. 2006, 43:1621-1622.
16. Kaeser H.E. Drug-induced myasthenic syndromes. Acta Neurol. Scand. Suppl. 1984, 100:39-47.
17. Kurtzke J.F., Kurland L.T. The epidemiology of neurologic disease. Clinical Neurology 1992, vol. 4:80-88. J.B. Lippincott, Philadelphia, (Chapter 66). Rev. ed.
18. LAREB Signals, 2003. Macrolide antibiotics and myasthenia. http://www.lareb.nl/kennis/zoeksignalen.asp.
19. Lonks J.R., Goldmann D.A. Telithromycin: a ketolide antibiotic for treatment of respiratory tract infections. Clin. Infect. Dis. 2005, 40:1657-1664.
20. Luther M.A., Schoepfer R., Whiting P., Casey B., Blatt Y., Montal M.S., Montal M., Linstrom J. A muscle acetylcholine receptor is expressed in the human cerebellar medulloblastoma cell line TE671. J. Neurosci. 1989, 9:1082-1096.
21. Magleby K.L., Pallotta B.S., Terrar D.A. The effect of (+)-tubocurarine on neuromuscular transmission during repetitive stimulation in the rat, mouse, and frog. J. Physiol. 1981, 312:97-113.
22. May E.F., Calvert P.C. Aggravation of myasthenia gravis by erythromycin. Ann. Neurol. 1990, 28:577-579.
23. Moreno A.P.J., Madurga S.M. Telithromycin and exacerbation in myasthenia gravis. Farm. Hosp. 2003, 27:199-200.
24. Nguyen M., Chung E.P. Telithromycin: the first ketolide antimicrobial. Clin. Ther. 2005, 27:1144-1163.
25. Nguyen-Huu T., Molgó J., Servent D., Duvaldestin P. Resistance to d-tubocurarine of the rat diaphragm as compared to a limb muscle: influence of quantal transmitter release and nicotinic acetylcholine receptors. Anesthesiology 2009, 110:1011-1115.
26. Nieman R.B., Sharma K., Edelberg H., Caffe S.E. Telithromycin and myasthenia gravis. Clin. Infect. Dis. 2003, 37:1579.
27. Pagala M.K., Namba T., Grob D. Desensitization to acetylcholine at motor end plates in normal humans, patients with myasthenia gravis, and experimental models of myasthenia gravis. Ann. N. Y. Acad. Sci. 1981, 377:567-582.
28. Perrot X., Bernard N., Vial C., Antoine J.C., Laurent H., Vial T., Confavreux C., Vukusic S. Myasthenia gravis exacerbation or unmasking associated with telithromycin treatment. Neurology 2006, 67:2256-2258.
29. Pihl J., Karlsson M., Chiu D.T. Microfluidic technologies in drug discovery. Drug Discov. Today 2005, 10:1377-1383.
30. Pijpers E., van Rijswijk R.E., Takx-Kohlen B., Schrey G. A clarithromycin-induced myasthenic syndrome. Clin. Infect. Dis. 1996, 22:175-176.
31. Schoepfer R., Luther M., Lindstrom J. The human medulloblastoma cell line TE671 expresses a muscle-like acetylcholine receptor. Cloning of the alpha-subunit cDNA. FEBS Lett. 1988, 226:235-240.
32. Shao Z., Mellor I.R., Brierley M.J., Harris J., Usherwood P.N. Potentiation and inhibition of nicotinic acetylcholine receptors by spermine in the TE671 human muscle cell line. J. Pharmacol. Exp. Ther. 1998, 286:1269-1276.
33. Sheridan R.E., Lester H.A. Rates and equilibria at the acetylcholine receptor of electrophorus electroplaques: a study of neurally evoked postsynaptic currents and of voltage-jump relaxations. J. Gen. Physiol. 1977, 70:187-219.
34. Shlaes D.M., Moellering R.C. Telithromycin and the FDA: implications for the future. Lancet Infect. Dis. 2008, 8:83-85.
35. Sine S.M. Functional properties of human skeletal muscle acetylcholine receptors expressed by the TE671 cell line. J. Biol. Chem. 1988, 263:18052-18062.
36. Yamamoto T., Vincent A., Ciulla T.A., Lang B., Johnston I., Newsom-Davis J. Seronegative myasthenia gravis: a plasma factor inhibiting agonist-induced acetylcholine receptor function copurifies with IgM. Ann. Neurol. 1991, 30:550-557.